 Inventiva NASDAQ: IVA announced the results of a clinical thorough QTQTc study demonstrating the safety of lanifibranor on cardiac electrical activity. The assessment of lanifibranor on cardiac repolarization was conducted under FDA in Phase 1 double-blind clinical trial to be included in the marketing application package of lanifibranor for the treatment of NASH. 